research Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells
Canagliflozin helps overcome progestin resistance in certain endometrial cancer cells.
Search
for
Sort by
Research
630-660 / 1000+ resultsresearch Nilotinib-induced generalized keratosis pilaris: Report of a rare case
Nilotinib can cause generalized keratosis pilaris.
research Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
research Analyzing the role of tofacitinib in treatment of alopecia areata: A retrospective analysis from a tertiary care center of North India
Tofacitinib effectively reduced hair loss in alopecia areata patients without adverse effects.
research Effectiveness of baricitinib in severe alopecia areata in real life: a retrospective study of 87 patients.
Baricitinib is effective and safe for treating severe alopecia areata.
research Delayed onset perforating folliculitis associated with sorafenib
Sorafenib can cause delayed skin problems, so patients need careful monitoring.
research Alopecia Areata Following the Use of Belimumab in a Patient with Systemic Lupus Erythematosus and Arthritis Who Responded Well to Baricitinib: A Case Report
Baricitinib improved hair loss and arthritis in a lupus patient.
research Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients
Deuruxolitinib effectively improves hair regrowth in alopecia areata but requires monitoring for side effects.
research Trachyonychia secondary to pediatric alopecia areata responding to oral tofacitinib therapy: a case report and review of literature
Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research The management of EGFR inhibitor adverse events: a case series and treatment paradigm
Skin side effects from EGFR inhibitor cancer treatment can be managed effectively, often without stopping the medication.
research Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Long‐Term Real‐World Outcomes of Baricitinib in Severe Alopecia Areata: A 104‐Week Retrospective Analysis From a Single Institute
Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
research Responses to Tetanus and Meningococcal Vaccines in Patients with Alopecia Areata Treated with Ritlecitinib
research Antibody Drug Conjugates
Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
research Baricitinib-Induced Trichilemmal Cyst Reactivation in a Woman With Alopecia Areata
Baricitinib may reactivate trichilemmal cysts in people with a history of these cysts.
research Folliculitis decalvans associated with erlotinib
Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
research Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.
research Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.
research Patient Profile and Treatment Characteristics of Early Ritlecitinib Initiators in the US
Ritlecitinib provides new treatment options for diverse alopecia areata patients.
research 증례 : Gefitinib에 의해 유발된 반흔성 탈모증
Gefitinib can cause rare scarring hair loss.
research Cutaneous toxicities of new treatments for melanoma
New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
research Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild‐type and BK5.AktWT mice
Rapamycin reduces skin cell growth and tumor development by affecting cell signaling in mice.
research Tumor Necrosis Factor-α and Interleukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice
Blocking certain proteins can reduce skin inflammation caused by cancer treatment.
research Differences in activation of β-catenin in outer root sheath cells between the type of JAK inhibitor: An alternative mechanism promoting hair growth by JAK inhibitors in alopecia areata
research Adverse Effects and Drug Interactions of Biologic Agents
Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.
research 566 Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity
ATR04-484 ointment shows promise for treating skin issues from cancer therapies.